Wed, Jul 30, 2014, 3:21 AM EDT - U.S. Markets open in 6 hrs 9 mins

Recent

% | $
Click the to save as a favorite.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

  • zwerp2000 zwerp2000 Jan 8, 2013 12:40 PM Flag

    Aptuit and Aegerion sign commercial API supply agreement

    Aptuit and Aegerion sign commercial API supply agreement
    Stuart Needleman, President and CEOO, Aptuit, announced that Aptuit and Aegerion Pharmaceuticals (AEGR), Cambridge, Massachusetts, have signed a long-term supply agreement for commercial quantities of the active pharmaceutical ingredient lomitapide. Lomitapide is Aegerion's orphan drug that is targeted to the treatment of a rare disease caused by a genetic disorder. The drug received NDA approval in December of 2012 and is expected to be launched commercially in January of 2013. Previously, Aptuit scientists had established the chemistry for lomitapide, developed and validated its analytical methods, delivered solid state form control and crystallization R&D, and supplied registration ba tches of material. Post-launch, Aptuit will continue to supply commercial quantities of lomitapide to Aegerion.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
AEGR
30.62+0.55(+1.83%)Jul 29 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Twitter, Inc.
NYSETue, Jul 29, 2014 4:04 PM EDT
El Pollo Loco Holdings, Inc.
NasdaqGSTue, Jul 29, 2014 4:00 PM EDT
Windstream Holdings, Inc.
NasdaqGSTue, Jul 29, 2014 4:00 PM EDT